Participants
Sixty-six anosmia related COVID -19 adult patients, 36 females and 30 males, were recruited during a period from August 2020 to January 2021 for this prospective trial study. Patients provided written informed consent for their medical records before participating in this study. Only patients over the age of 18 with history of confirmed COVID-19 and olfactory dysfunction persisted more than 90 days after SARS-CoV-2 negative testing were included. Patients with neurodegenerative or other conditions affecting olfaction were excluded. The patient characteristics were recorded for each participant.